FDA to Review Schering-Plough's Asenapine NDA
Posted on: Tuesday, 27 November 2007, 09:01 CST
The FDA has accepted Schering-Plough's new drug application for asenapine, a fast-dissolving, sublingual tablet for schizophrenia, for review.
Schering-Plough is seeking marketing approval from the FDA for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar I disorder.
In accepting the new drug application (NDA), the FDA indicated that asenapine will receive a standard review.
The clinical trial program thus far has consisted of schizophrenia and bipolar mania trials involving nearly 3,000 patients.
Schering-Plough acquired asenapine through its combination with Organon BioSciences on November 19, 2007.
Source: Datamonitor
Related Articles
- Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
- Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
- FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
- Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
- Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
- U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
- Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status By U.S. FDA
- Schering-Plough Announces Asenapine NDA Accepted for Filing By the U.S. FDA
- Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
Rating: 3.4 / 5 (5 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds